Okla. Stat. tit. 63, § 63-2-210: Schedule IV

A. Any material, compound, mixture, or preparation which

contains any quantity of the following substances having a potential

for abuse associated with a stimulant or depressant effect on the

central nervous system:

1. Chloral betaine;

2. Chloral hydrate;

3. Ethchlorvynol;

4. Ethinamate;

5. Meprobamate;

6. Paraldehyde;

7. Petrichloral;

8. Diethylpropion;

9. Phentermine;

10. Pemoline;

11. Chlordiazepoxide;

12. Chlordiazepoxide and its salts, but not including

chlordiazepoxide hydrochloride and clidinium bromide or

chlordiazepoxide and water-soluble esterified estrogens;

13. Diazepam;

14. Oxazepam;

15. Clorazepate;

16. Flurazepam and its salts;

17. Clonazepam;

18. Barbital;

19. Mebutamate;

20. Methohexital;

21. Methylphenobarbital;

22. Phenobarbital;

23. Fenfluramine;

24. Pentazocine;

25. Propoxyphene;

26. Butorphanol;

27. Alprazolam;

28. Halazepam;

29. Lorazepam;

30. Prazepam;

31. Temazepam;

32. Triazolam;

33. Carisoprodol;

34. Dichloralphenazone;

35. Estazolam;

36. Eszopiclone;

37. Midazolam;

38. Modafinil;

39. Zaleplon;

40. Zolpidem;

41. Tramadol;

42. Bromazepam;

43. Suvorexant;

44. Phenazepam;

45. Etizolam; or

46. Clonazolam.

B. 1. The following nonnarcotic substances, which may, under

the Federal Food, Drug, and Cosmetic Act (21 U.S.C., Section 301),

be lawfully sold over the counter without a prescription, are

excluded from all schedules of controlled substances under this

title:

a. Breathe-Aid,

b. BronCare,

c. Bronchial Congestion,

d. Bronkaid Tablets,

e. Bronkaid Dual Action Caplets,

f. Bronkotabs,

g. Bronkolixir,

h. NeoRespin,

i. Pazo Hemorrhoid Ointment and Suppositories,

j. Primatene Tablets,

k. Primatene "Dual Action" Formula,

l. Quelidrine,

m. Resp, and

n. Vatronal Nose Drops.

2. At the request of any person, the Director may exempt any

other drug product containing ephedrine from being included as a

Schedule IV controlled substance if such product:

a. is labeled and marketed in a manner consistent with

the pertinent OTC tentative final or final monograph

issued by the FDA, and

b. is manufactured and distributed for legitimate

medicinal use and in a manner that reduces or

eliminates the likelihood of abuse.

3. In making a determination regarding a drug product, the

Director, after notice and hearing, shall consider the following:

a. the history and current pattern of abuse,

b. the name and labeling of the product,

c. the intended manner of distribution, advertising and

promotion of the product, and

d. other factors as may be relevant to and consistent

with the public health and safety.

4. The hearing shall be held in accordance with the

Administrative Procedures Act.

5. A list of current drug products meeting exemption

requirements under this subsection may be obtained from the Bureau

upon written request.

C. The Board of Pharmacy may except by rule any compound,

mixture, or preparation containing any depressant substance listed

in subsection A of this section from the application of all or any

part of the Uniform Controlled Dangerous Substances Act, Section 2-

101 et seq. of this title, if the compound, mixture, or preparation

contains one or more active medicinal ingredients not having a

depressant effect on the central nervous system, and if the

admixtures are included therein in combinations, quantity,

proportion, or concentration that vitiate the potential for abuse of

the substances which have a depressant effect on the central nervous

system.